EWTX Edgewise Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1710072 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY742.1%
TTM EPS YoY633.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE92.1%
ROA85.4%
ROIC (approx.)-16.6%
Asset turnover—
Leverage & solvency
Liabilities / assets8.3%
Debt / equity0.00x
Current ratio12.30x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-0.20x
Accruals ratio102.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $151.39M | $126.97M |
| SG&A expense | $40.02M | $31.87M |
| Operating income | -$191.41M | -$158.83M |
| Pretax income | -$167.80M | -$133.80M |
| Income tax | $4,000 | $3,000 |
| Net income | -$167.79M | -$133.81M |
| EBITDA | -$189.32M | -$156.76M |
| EPS (basic) | -1.63 | -1.45 |
| EPS (diluted) | -1.63 | -1.45 |
| Weighted avg. shares (diluted) | 102.93M | 92.41M |
| Balance sheet | ||
| Cash & equivalents | $61.15M | $41.67M |
| Current assets | $543.38M | $475.48M |
| PP&E, net | $7.83M | $9.50M |
| Total assets | $552.60M | $486.82M |
| Current liabilities | $27.37M | $23.86M |
| Total liabilities | $30.35M | $27.60M |
| Shareholders' equity | $522.26M | $459.22M |
| Shares outstanding | 106.25M | 94.84M |
| Cash flow statement | ||
| Operating cash flow | -$143.82M | -$109.03M |
| Capital expenditure | $256,000 | $1.31M |
| Free cash flow | -$144.07M | -$110.34M |
| Investing cash flow | -$32.79M | -$184.66M |
| Financing cash flow | $196.09M | $249.25M |
| Depreciation & amortization | $2.08M | $2.07M |
| Stock-based compensation | $34.75M | $24.71M |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.